Copyright Notice
Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.
Bookshelf ID: NBK594972PMID: 37748010
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.
CASRN: 1025504-45-3
Drug Levels and Effects
Summary of Use during Lactation
No information is available on the use of valbenazine during breastfeeding in humans. Based on animal studies, the manufacturer recommends that breastfeeding be avoided during valbenazine therapy and for 5 days after the final dose.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Substance Identification
Substance Name
Valbenazine
CAS Registry Number
1025504-45-3
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- User and Medical Advice Disclaimer
- Drugs and Lactation Database (LactMed) - Record Format
- LactMed - Database Creation and Peer Review Process
- Fact Sheet. Drugs and Lactation Database (LactMed)
- Drugs and Lactation Database (LactMed) - Glossary
- LactMed Selected References
- Drugs and Lactation Database (LactMed) - About Dietary Supplements
- Breastfeeding Links
- PubChem SubstanceRelated PubChem Substances
- Synthesis of potential antineoplastic agents XXVI: 1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-2H-benzo[a]2-quinolizinone derivatives.[J Pharm Sci. 1978]Synthesis of potential antineoplastic agents XXVI: 1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-2H-benzo[a]2-quinolizinone derivatives.Popp FD, Watts RF. J Pharm Sci. 1978 Jun; 67(6):871-3.
- Synthesis and antihypertensive activity of a series of spiro[1,3,4,6,7,11b-hexahydro-2H-benzo[a]quinolizine-2,5'-oxazolidin-2'-one]s.[J Med Chem. 1983]Synthesis and antihypertensive activity of a series of spiro[1,3,4,6,7,11b-hexahydro-2H-benzo[a]quinolizine-2,5'-oxazolidin-2'-one]s.Caroon JM, Clark RD, Kluge AF, Lee CH, Strosberg AM. J Med Chem. 1983 Oct; 26(10):1426-33.
- Review Lovastatin.[Drugs and Lactation Database (...]Review Lovastatin.. Drugs and Lactation Database (LactMed®). 2006
- Pharmacologic Characterization of Valbenazine (NBI-98854) and Its Metabolites.[J Pharmacol Exp Ther. 2017]Pharmacologic Characterization of Valbenazine (NBI-98854) and Its Metabolites.Grigoriadis DE, Smith E, Hoare SRJ, Madan A, Bozigian H. J Pharmacol Exp Ther. 2017 Jun; 361(3):454-461. Epub 2017 Apr 12.
- Review Valbenazine for the treatment of tardive dyskinesia.[Drugs Today (Barc). 2016]Review Valbenazine for the treatment of tardive dyskinesia.Barquero N. Drugs Today (Barc). 2016 Dec; 52(12):665-672.
- Valbenazine - Drugs and Lactation Database (LactMed®)Valbenazine - Drugs and Lactation Database (LactMed®)
Your browsing activity is empty.
Activity recording is turned off.
See more...